Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So sounds like you are expecting news to coincide with this event.
Actually my buy showed as a sell.
The only thing I can agree with what you say is that management need to speak up and let us know what’s going on.
The facts are that the company has a market cap of around 8.5 million with around 6.5 million in cash. There is no way on earth with revenue of 40 million a year the current share price reflects the company, it’s way to cheap.
Now when and if management make comment you would think share price should rise.
Some open market buys by management would really do the trick.
Thanks Bear, slides 9-10 all about RXMD. Interesting they still have 1Q 2023, so should see something very soon.
“Investment to accelerate Progressive's digital healthcare transformation and launch of a global e-commerce platform for new healthcare and lifestyle products”
From what I read, looks like we should have a major online revenue stream being created.
Let’s hope so Stock, we are certainly due for some sort of update.
I think we need some love like NXPL, shares up nicely again.
New tweet from Remsleep;
RMSL is pleased to announce that it has finalized the design and commissioned the tooling for a disposable version of the DeltaWave - initial designation LifeGuard. The LifeGuard has the potential to treat COPD and CH patients in
Institutions and at home. The company also has 2 design patents, and a CIP
pending. One should issue shortly. The company has run into a delay with the cytoxicity testing. There is one component of the DeltaWave that requires a retest. We now expect testing to be finalized by the end of May. This retest was unexpected, disappointing to all. We are
not expecting any further delays. We remain committed to the goal of bringing the
DeltaWave to market at the earliest opportunity”
NXPL filed proxy for annual meeting today;
“
You are cordially invited to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of NextPlat Corp (the “Company”). The Annual Meeting will be held virtually at 10:00 AM Eastern Daylight Time on May 31, 2023, or at such other time or such other date to which the meeting may be adjourned. The Annual Meeting will be a virtual meeting to be held as a listen-only conference call. There will not be a physical meeting location.”
Well NXPL doing well last few days
So much in NXPL earnings which mentioned Healtcare as driving force of NXPL’s future;
“Mr. Fernandez concluded, "Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth healthcare market where we intend to launch an array of innovative new offerings. Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands, and industries in the United States and abroad."
Think you will find our CEO holds a lot of that debt.
Just need to know what the plan is now.
I think we will get news very soon, certainly expecting some commentary from company re 10k and future plans next week.
Would love to see some insider open market purchases, now that would get the stock moving up.
Thanks, I believe we get an update very soon.
What chat site was that on
I have not looked but was reduction in margin due to less Covid income which was higher profit.
If they want to expand of course they may raise cash. They have 6,7 million in cash and 3 million or so shares outstanding.
10k just filed
It’s coming this week.
SAN DIEGO, March 17, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, announced that on March 16, 2023, the LA County Superior Court confirmed an arbitration award of $125 million in damages, to be paid by NantPharma, LLC ("NantPharma"). The award reflects the values of lost milestones for the approval of the drug Cynviloq® for the treatment of breast and lung cancers.
Did you notice this from filing just out;
“In addition, warrants to purchase up to an aggregate of 3,495,000 Ordinary Shares which were previously issued to the purchaser in a private placement consummated by the Company in November 2022 and have an exercise price of $1.73 per share were cancelled simultaneously with the closing of this Offering.”
Most important thing is that’s it’s been sorted, whatever the issue was.
Just filed, something small to cheer about;
“As Progressive Care, Inc. (the “Company”) previously reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on January 20, 2023, the Company had received notice that one of its third-party payors had declined to renew its agreement with one of the Company’s pharmacy locations (the “Contract”). The Contract had previously been set to renew as of February 24, 2023. On January 19, 2023, the Company reached an agreement with the third-party payor to extend the Contract term until April 24, 2023 to facilitate continued negotiations with respect to extending the term of the Contract.
On February 28, 2023, the Company and such third-party payor entered into an agreement pursuant to which the Contract will continue on its terms, subject to the Company maintaining compliance with certain required procedures.”
From what I can see, is that they have done this to protect assets from PSS. SRNE could easily have dealt with this if they wanted to, but probably did not want to sell assets at a low ball, and did not want to dilute at current levels. I mean they holding alone in SCLX could have paid off PSS 10 fold.
I agree it’s time for the plan
Stock what’s your thoughts on withdrawal of S-1
Makes sense to keep all in house. Was clear with same CEO and CFO that companies are likely to merge at some point, well we can presume that is most likely the scenario.Would also think that they could save a lot of costs if the do merge
Quiet period officially over, news forthcoming I believe
NXPL has been getting a bit of a bid the last few days, let’s hope it’s an indication of news.
Yes yesterday and today, no issues buying.
Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31.
Analyst James Molloy writes that his recommendation is based primarily on expectations for Hepion’s rencofilstat, a cyclophilin inhibitor that is being developed to treat non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) associated with NASH.
Trading on scotiaitrade
Should we not go back to RXMD today
Do people not think that SRNE has been super quiet, like they are in a quiet period or something.
Not getting out of this;
MedAvail - The company also affirms its guidance of 40 new net dispensing deployments for full year 2022.
Still deploying dispensing units.
On several other boards those that use TD have not had theirs yet.